We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

101 hedge funds and large institutions have $342M invested in Pacific Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 31 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

113% more call options, than puts

Call options by funds: $540K | Put options by funds: $253K

93% more capital invested

Capital invested by funds: $178M → $342M (+$164M)

15% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 27

15% more funds holding

Funds holding: 88 → 101 (+13)

Holders
101
Holders Change
+13
Holders Change %
+14.77%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
31
Reduced
27
Closed
10
Calls
$540K
Puts
$253K
Net Calls
+$287K
Net Calls Change
+$209K

Top Buyers

1
DM
Deerfield Management
New York
+$4.62M
2
BG
BlackRock Group
United Kingdom
+$4.13M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.16M
4
Millennium Management
Millennium Management
New York
+$1.82M
5
IG
ING Group
Netherlands
+$1.6M

Top Sellers

1
RCM
Raging Capital Management
New Jersey
-$7.75M
2
Goldman Sachs
Goldman Sachs
New York
-$2.16M
3
BIM
Bogle Investment Management
Massachusetts
-$1.01M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$646K
5
PPA
Parametric Portfolio Associates
Washington
-$640K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$440K +$199K +31,062 +124%
VOYA Investment Management
52
VOYA Investment Management
Georgia
$405K – – –
SO
53
STRS Ohio
Ohio
$397K +$915 +143 +0.3%
Swiss National Bank
54
Swiss National Bank
Switzerland
$376K +$307K +48,000 New
Goldman Sachs
55
Goldman Sachs
New York
$358K -$2.16M -337,883 -88%
MLICM
56
Metropolitan Life Insurance Company (MetLife)
New York
$334K – – –
Citadel Advisors
57
Citadel Advisors
Florida
$327K +$222K +34,633 +493%
JP Morgan Chase
58
JP Morgan Chase
New York
$310K +$253K +39,500 New
DekaBank Deutsche Girozentrale
59
DekaBank Deutsche Girozentrale
Germany
$286K -$22.4K -3,500 -8%
AIG
60
American International Group
New York
$284K -$9.16K -1,431 -4%
GCP
61
GSA Capital Partners
United Kingdom
$248K -$205K -32,044 -50%
DC
62
Deere & Company
Illinois
$246K -$85.7K -13,394 -30%
Citigroup
63
Citigroup
New York
$210K +$156K +24,304 +963%
CIA
64
Capital Impact Advisors
Massachusetts
$207K – – –
T. Rowe Price Associates
65
T. Rowe Price Associates
Maryland
$185K -$97.3K -15,200 -39%
WA
66
WFG Advisors
Texas
$184K +$5.44K +850 +4%
PP
67
Paloma Partners
Connecticut
$180K +$52.5K +8,200 +56%
Squarepoint
68
Squarepoint
New York
$176K +$143K +22,400 New
William Blair & Company
69
William Blair & Company
Illinois
$164K – – –
CSS
70
Cubist Systematic Strategies
Connecticut
$154K +$41K +6,400 +48%
UBS AM
71
UBS AM
Illinois
$146K +$119K +18,600 New
Wells Fargo
72
Wells Fargo
California
$135K +$93.5K +14,611 +552%
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$132K +$108K +16,847 New
Principal Financial Group
74
Principal Financial Group
Iowa
$125K -$18K -2,808 -15%
State Board of Administration of Florida Retirement System
75
State Board of Administration of Florida Retirement System
Florida
$124K – – –
1 2
3
4 5

PACB Hedge Fund Activity: Q4 2014 in Review

101 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2014, worth a combined $342M — up 93% from $178M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PACB positions and 10 closed out — a net gain of 15 holders — while 31 added to existing stakes and 27 trimmed.

The largest buyer was Deerfield Management, adding an estimated $4.62M. The largest seller was Raging Capital Management, exiting entirely with an estimated $7.75M sold.

  • 101 institutional investors held Pacific Biosciences (PACB) as of Q4 2014, up from 88 in Q3 2014.
  • Funds reported $342M of Pacific Biosciences stock for Q4 2014, up 93% quarter-over-quarter.
  • 25 funds opened new Pacific Biosciences positions in Q4 2014 and 10 closed out, a net change of +15 holders.
  • The largest Pacific Biosciences buyer in Q4 2014 was Deerfield Management, an estimated $4.62M added.
  • The largest Pacific Biosciences seller in Q4 2014 was Raging Capital Management, an estimated $7.75M sold.

Based on aggregated 13F filings for Q4 2014.